Bemnifosbuvir - Atea Pharmaceuticals
Alternative Names: AT-511-hemisulfate salt; AT-527 free base; AT‐527; RG-6422; RO 7496998Latest Information Update: 09 Aug 2024
At a glance
- Originator Atea Pharmaceuticals
- Class Amines; Antivirals; Esters; Fluorinated hydrocarbons; Phosphorus compounds; Purine nucleotides; Small molecules
- Mechanism of Action DNA-directed RNA polymerase inhibitors; Hepatitis C virus NS 5 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III COVID 2019 infections
- Phase II Hepatitis C
Most Recent Events
- 30 Jun 2024 Atea Pharmaceuticals completes enrolment in its phase II trial in Hepatitis C (Combination therapy) in USA, Brazil, Canada, India, South Korea, Mauritius, Moldova, Pakistan, Philippines, Romania, South Africa and Turkey (PO) (NCT05904470)
- 15 Jun 2024 Atea Pharmaceuticals completes a phase I pharmacokinetic and safety trial in patients with various degrees of renal insufficiency in Canada (PO) (NCT05618314)
- 05 Jun 2024 Adverse events data from the phase II trial in Hepatitis C presented at the European Association for the Study of the Liver Congress (EASL-2024)